Merck on Tuesday issued full-year 2025 revenue ... The company said that sales range reflects a decision to halt shipments of ...

In the first meeting of the Centers for Disease Control and Prevention's Advisory Committee on Immunization Practices (ACIP) ...

Leaders at Merck & Co. Inc. are facing a new derivative shareholder lawsuit over allegations that they made misleading ...

A class action lawsuit was filed against Merck & Co. (MRK) by Levi & Korsinsky on February 12, 2025. The plaintiffs ...

Gardasil vaccine protects against cancer-causing human papilloma virus or HPV infections. The pause announcement comes a month after Merck received approval in China for use of the vaccine in males.

Rising competitive pressure on the diabetes franchise and persistent challenges for its human papillomavirus vaccine, Gardasil in China remain overhangs. There are concerns about Merck’s ability ...

Merck does have other products that can also generate billions in revenue in the future. Gardasil, its vaccine for the human papillomavirus (HPV), may generate $11 billion in revenue by 2030 ...

Merck withdrew its previously issued long-term guidance of generating more than $11 billion in sales form Gardasil by 2030. Proquad, M-M-R II and Varivax vaccines recorded combined sales of $594 ...

NEW YORK, NY / ACCESS Newswire / April 13, 2025 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, ...

Further, Merck’s earnings should grow faster as royalty payments on human papillomavirus vaccine Gardasil and Keytruda fall in 2024. Merck: Posts Leading Early-Stage Keytruda Data in Lung Cancer ...